The proportion of HIV-infected patients aged >=65 years is projected to nearly triple between 2010 to 2030, from 8.5% to 21.4% in Western countries.7 The number of patients enrolled in the HIV-lymphoma cohort was relative stable over time, with an increased incidence rate of MCL during recent years as half of the cases were diagnosed in the past 4 years. This result should be interpreted with caution due to the small number of patients and the context of COVID-19 pandemic and should not prevent treating these patients according to the current guidelines with up-front ASCT when feasible and rituximab maintenance therapy. Mantle cell lymphoma (MCL) is a rare subtype of lymphoid malignancy, representing 5%-7% of adult-onset non-Hodgkin lymphoma (NHL) in Western countries, but with a rising incidence.1 Most patients with MCL have an aggressive disease. [Extracted from the article]